ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1746

Thrombotic Microangiopathy and AKI Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Hanna, Ramy Magdy, University of California Irvine, Orange, California, United States
  • Patel, Sapna Singh, Long Beach Medical Center, Long Beach, California, United States
  • Tran, Ngoc Gia, Long Beach Medical Center, Long Beach, California, United States
  • Jhaveri, Kenar D., Northwell Health, Great Neck, New York, United States
  • Kalantar-Zadeh, Kamyar, University of California Los Angeles, Los Angeles, California, United States
  • Kurtz, Ira, University of California Los Angeles, Los Angeles, California, United States
Introduction

Vascular Endothelial Growth Factor (VEGF) inhibition can cause worsening hypertension, proteinuria, acute and chronic kidney injury, as well as glomerular disease from Thrombotic Microangiopathy (TMA) and other nephrotic disorders when given systemically. These same agents are given intravitreally for age related macular degeneration (AMD) and Diabetic Retinopathy (DR) among other ophthalmologic conditions, albeit at lower doses than those given for systemic indications. Systemic absorption of anti-VEGF agents when given intravitreally has been shown consistently along with evidence of significant intravascular VEGF suppression. While worsening hypertension has only been seen in some large-scale studies, case reports show worsening proteinuria and diverse glomerular diseases. These include TMA-associated lesions like Focal and Segmental Glomerulosclerosis with Collapsing Features (cFSGS).

Case Description

In this paper, we report 3 cases of TMA likely associated with use of intravitreal anti VEGF therapy. These patients developed the signature lesion of VEGF blockade in a 6 month – 11-month time frame after starting intravitreal VEGF inhibitors.

Discussion

The literature is reviewed showing similar cases. Intravitreal VEGF blockade may cause these adverse events in a hitherto unidentified subgroup of patients. Further studies are needed to determine the event rate and identify which patients are at increased risk for hypertension, proteinuria worsening, renal injury, and glomerular diseases from intravitreal VEGF blockade.